Login / Signup

Paucity of intellectual property rights information in the US biologics system a decade after passage of the Biosimilars Act.

Robin C Feldman
Published in: PLoS medicine (2024)
In this Policy Forum piece, Robin Feldman discusses how current legislation contributes to informational deficits around drug patents for biologic drugs in the United States.
Keyphrases
  • rheumatoid arthritis
  • public health
  • healthcare
  • traumatic brain injury
  • drug induced
  • mental health
  • health information
  • adverse drug
  • emergency department